Test positivity for common cold coronaviruses significantly declined following widespread SARS-CoV-2 infection and COVID-19 ...

Gilead Sciences has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two midstage ...

Research shows RSV leads to high hospitalization rates in adults, emphasizing the importance of enhanced surveillance and ...

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

Two AS01-adjuvanted vaccines for different pathogens -- the respiratory syncytial virus (RSV) vaccine (Arexvy) and the ...

CDC panel backs Merck's Enflonsia for RSV prevention in infants; FDA-approved therapy reduced hospitalizations by 84% in ...

The risk for severe RSV-related outcomes was effectively reduced among children and infants who received nirsevimab in real-world clinical settings.

Merck’s Enflonsia receives US FDA approval for prevention of RSV lower respiratory tract disease in infants born during or entering their first RSV season ...

Merck's Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention's ...

A second monoclonal antibody to prevent respiratory syncytial virus (RSV) in infants has been recommended by the CDC’s Advisory Committee on Immunization Practices (ACIP). Five members voted yes ...

Children under 5 with RSV or flu face higher bacteremia risk if febrile, under 6 months, or need respiratory support, with ...

Compared with flu vaccine recipients, those given the RSV or shingles vaccine had 18% to 37% lower odds of receiving a ...